Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
Identifieur interne : 000640 ( PubMed/Curation ); précédent : 000639; suivant : 000641Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
Auteurs : Dirk Schadendorf [Allemagne] ; Georgina V. Long [Australie] ; Daniil Stroiakovski [Russie] ; Boguslawa Karaszewska [Pologne] ; Axel Hauschild [Allemagne] ; Evgeny Levchenko [Russie] ; Vanna Chiarion-Sileni [Italie] ; Jacob Schachter [Israël] ; Claus Garbe [Allemagne] ; Caroline Dutriaux [France] ; Helen Gogas [Grèce] ; Mario Mandalà [Italie] ; John B A G. Haanen [Pays-Bas] ; Céleste Lebbé [France] ; Andrzej Mackiewicz [Pologne] ; Piotr Rutkowski [Pologne] ; Jean-Jacques Grob [France] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Michael A. Davies [États-Unis] ; Ying Zhang [États-Unis] ; Mathilde Kaper [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Keith T. Flaherty [États-Unis] ; Caroline Robert [France]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse de survie, Facteurs de risque, Femelle, Humains, Imidazoles (administration et posologie), Inhibiteurs de protéines kinases (usage thérapeutique), L-Lactate dehydrogenase (métabolisme), Mâle, Mélanome (anatomopathologie), Mélanome (métabolisme), Mélanome (traitement médicamenteux), Métastase tumorale (anatomopathologie), Oximes (administration et posologie), Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Pyridones (administration et posologie), Pyrimidinones (administration et posologie), Sujet âgé, Valeur prédictive des tests.
- MESH :
- administration et posologie : Imidazoles, Oximes, Pyridones, Pyrimidinones.
- anatomopathologie : Mélanome, Métastase tumorale.
- métabolisme : L-Lactate dehydrogenase, Mélanome.
- traitement médicamenteux : Mélanome.
- usage thérapeutique : Inhibiteurs de protéines kinases, Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Analyse de survie, Facteurs de risque, Femelle, Humains, Mâle, Pronostic, Sujet âgé, Valeur prédictive des tests.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Female, Humans, Imidazoles (administration & dosage), L-Lactate Dehydrogenase (metabolism), Male, Melanoma (drug therapy), Melanoma (metabolism), Melanoma (pathology), Middle Aged, Neoplasm Metastasis (pathology), Oximes (administration & dosage), Predictive Value of Tests, Prognosis, Protein Kinase Inhibitors (therapeutic use), Pyridones (administration & dosage), Pyrimidinones (administration & dosage), Risk Factors, Survival Analysis.
- MESH :
- chemical , administration & dosage : Imidazoles, Oximes, Pyridones, Pyrimidinones.
- chemical , metabolism : L-Lactate Dehydrogenase.
- drug therapy : Melanoma.
- metabolism : Melanoma.
- pathology : Melanoma, Neoplasm Metastasis.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Protein Kinase Inhibitors.
- Adult, Aged, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Risk Factors, Survival Analysis.
Abstract
Understanding predictors of long-term benefit with currently available melanoma therapies is the key for optimising individualised treatments. A prior pooled analysis of dabrafenib plus trametinib (D + T)-randomised trials (median follow-up, 20.0 months) identified baseline lactate dehydrogenase (LDH) and number of organ sites with metastasis as predictive factors for progression-free (PFS) and overall (OS) survival. However, longer-term follow-up analyses are needed to confirm which patients treated with D + T can achieve maximum benefit.
DOI: 10.1016/j.ejca.2017.05.033
PubMed: 28648698
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000642
Links to Exploration step
pubmed:28648698Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.</title><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; German Cancer Consortium, 69117 Heidelberg, Germany. Electronic address: Dirk.Schadendorf@uk-essen.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; German Cancer Consortium, 69117 Heidelberg</wicri:regionArea></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, NSW, Australia; Mater Hospital, North Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melanoma Institute Australia, The University of Sydney, NSW, Australia; Mater Hospital, North Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW</wicri:regionArea></affiliation></author><author><name sortKey="Stroiakovski, Daniil" sort="Stroiakovski, Daniil" uniqKey="Stroiakovski D" first="Daniil" last="Stroiakovski">Daniil Stroiakovski</name><affiliation wicri:level="1"><nlm:affiliation>Moscow City Oncology Hospital No 62, Moscow 143423, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Moscow City Oncology Hospital No 62, Moscow 143423</wicri:regionArea></affiliation></author><author><name sortKey="Karaszewska, Boguslawa" sort="Karaszewska, Boguslawa" uniqKey="Karaszewska B" first="Boguslawa" last="Karaszewska">Boguslawa Karaszewska</name><affiliation wicri:level="1"><nlm:affiliation>Przychodnia Lekarska KOMED, Wojska Polskiego 6, 62-500 Konin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Przychodnia Lekarska KOMED, Wojska Polskiego 6, 62-500 Konin</wicri:regionArea></affiliation></author><author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Medical Center Schleswig-Holstein, Arnold-Heller-Straße 3, 24105 Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Medical Center Schleswig-Holstein, Arnold-Heller-Straße 3, 24105 Kiel</wicri:regionArea></affiliation></author><author><name sortKey="Levchenko, Evgeny" sort="Levchenko, Evgeny" uniqKey="Levchenko E" first="Evgeny" last="Levchenko">Evgeny Levchenko</name><affiliation wicri:level="1"><nlm:affiliation>Petrov Research Institute of Oncology, 68 Leningradskaya Street, Saint Petersburg 197758, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Petrov Research Institute of Oncology, 68 Leningradskaya Street, Saint Petersburg 197758</wicri:regionArea></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma and Esophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Via Gattamelata 64, 35128 Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma and Esophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Via Gattamelata 64, 35128 Padova</wicri:regionArea></affiliation></author><author><name sortKey="Schachter, Jacob" sort="Schachter, Jacob" uniqKey="Schachter J" first="Jacob" last="Schachter">Jacob Schachter</name><affiliation wicri:level="1"><nlm:affiliation>Oncology Division, Sheba Medical Center, Tel HaShomer, Emek HaEla St 1, Ramat Gan, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Oncology Division, Sheba Medical Center, Tel HaShomer, Emek HaEla St 1, Ramat Gan</wicri:regionArea></affiliation></author><author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University of Tübingen, Geschwister-Scholl-Platz, 72074 Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Tübingen, Geschwister-Scholl-Platz, 72074 Tübingen</wicri:regionArea></affiliation></author><author><name sortKey="Dutriaux, Caroline" sort="Dutriaux, Caroline" uniqKey="Dutriaux C" first="Caroline" last="Dutriaux">Caroline Dutriaux</name><affiliation wicri:level="1"><nlm:affiliation>Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Saint-André, 1 Rue Jean Burguet, 33000 Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Saint-André, 1 Rue Jean Burguet, 33000 Bordeaux</wicri:regionArea></affiliation></author><author><name sortKey="Gogas, Helen" sort="Gogas, Helen" uniqKey="Gogas H" first="Helen" last="Gogas">Helen Gogas</name><affiliation wicri:level="1"><nlm:affiliation>First Department of Medicine, "Laiko" General Hospital, National and Kapodistrian University of Athens, Athens 157 72, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>First Department of Medicine, "Laiko" General Hospital, National and Kapodistrian University of Athens, Athens 157 72</wicri:regionArea></affiliation></author><author><name sortKey="Mandala, Mario" sort="Mandala, Mario" uniqKey="Mandala M" first="Mario" last="Mandalà">Mario Mandalà</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo</wicri:regionArea></affiliation></author><author><name sortKey="Haanen, John B A G" sort="Haanen, John B A G" uniqKey="Haanen J" first="John B A G" last="Haanen">John B A G. Haanen</name><affiliation wicri:level="1"><nlm:affiliation>Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Céleste" last="Lebbé">Céleste Lebbé</name><affiliation wicri:level="1"><nlm:affiliation>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Mackiewicz, Andrzej" sort="Mackiewicz, Andrzej" uniqKey="Mackiewicz A" first="Andrzej" last="Mackiewicz">Andrzej Mackiewicz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cancer Immunology, Poznan University of Medical Sciences, 15 Garbary Street, 61-866 Poznań, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Cancer Immunology, Poznan University of Medical Sciences, 15 Garbary Street, 61-866 Poznań</wicri:regionArea></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Wawelska 15B, 02-034 Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Wawelska 15B, 02-034 Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Center, Timone Hospital, Aix Marseille University, 264 Rue St Pierre, 13885 Marseille Cedex 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, University Hospital Center, Timone Hospital, Aix Marseille University, 264 Rue St Pierre, 13885 Marseille Cedex 05</wicri:regionArea></affiliation></author><author><name sortKey="Nathan, Paul" sort="Nathan, Paul" uniqKey="Nathan P" first="Paul" last="Nathan">Paul Nathan</name><affiliation wicri:level="1"><nlm:affiliation>Mount Vernon Cancer Centre, Rickmansworth Road, HA6 2RN Northwood, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Mount Vernon Cancer Centre, Rickmansworth Road, HA6 2RN Northwood</wicri:regionArea></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Hematology/Oncology, UCLA Medical Center, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Hematology/Oncology, UCLA Medical Center, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA</wicri:regionArea></affiliation></author><author><name sortKey="Davies, Michael A" sort="Davies, Michael A" uniqKey="Davies M" first="Michael A" last="Davies">Michael A. Davies</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, TX</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Ying" sort="Zhang, Ying" uniqKey="Zhang Y" first="Ying" last="Zhang">Ying Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ</wicri:regionArea></affiliation></author><author><name sortKey="Kaper, Mathilde" sort="Kaper, Mathilde" uniqKey="Kaper M" first="Mathilde" last="Kaper">Mathilde Kaper</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ</wicri:regionArea></affiliation></author><author><name sortKey="Mookerjee, Bijoyesh" sort="Mookerjee, Bijoyesh" uniqKey="Mookerjee B" first="Bijoyesh" last="Mookerjee">Bijoyesh Mookerjee</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ</wicri:regionArea></affiliation></author><author><name sortKey="Legos, Jeffrey J" sort="Legos, Jeffrey J" uniqKey="Legos J" first="Jeffrey J" last="Legos">Jeffrey J. Legos</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ</wicri:regionArea></affiliation></author><author><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><affiliation wicri:level="1"><nlm:affiliation>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston 02114, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston 02114, MA</wicri:regionArea></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Dermatology Service, Gustave Roussy Comprehensive Cancer Center and Faculty of Medicine, University Paris-South, F-94805, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Dermatology Service, Gustave Roussy Comprehensive Cancer Center and Faculty of Medicine, University Paris-South, F-94805, Villejuif</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28648698</idno><idno type="pmid">28648698</idno><idno type="doi">10.1016/j.ejca.2017.05.033</idno><idno type="wicri:Area/PubMed/Corpus">000642</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000642</idno><idno type="wicri:Area/PubMed/Curation">000640</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000640</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.</title><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; German Cancer Consortium, 69117 Heidelberg, Germany. Electronic address: Dirk.Schadendorf@uk-essen.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; German Cancer Consortium, 69117 Heidelberg</wicri:regionArea></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, NSW, Australia; Mater Hospital, North Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melanoma Institute Australia, The University of Sydney, NSW, Australia; Mater Hospital, North Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW</wicri:regionArea></affiliation></author><author><name sortKey="Stroiakovski, Daniil" sort="Stroiakovski, Daniil" uniqKey="Stroiakovski D" first="Daniil" last="Stroiakovski">Daniil Stroiakovski</name><affiliation wicri:level="1"><nlm:affiliation>Moscow City Oncology Hospital No 62, Moscow 143423, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Moscow City Oncology Hospital No 62, Moscow 143423</wicri:regionArea></affiliation></author><author><name sortKey="Karaszewska, Boguslawa" sort="Karaszewska, Boguslawa" uniqKey="Karaszewska B" first="Boguslawa" last="Karaszewska">Boguslawa Karaszewska</name><affiliation wicri:level="1"><nlm:affiliation>Przychodnia Lekarska KOMED, Wojska Polskiego 6, 62-500 Konin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Przychodnia Lekarska KOMED, Wojska Polskiego 6, 62-500 Konin</wicri:regionArea></affiliation></author><author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Medical Center Schleswig-Holstein, Arnold-Heller-Straße 3, 24105 Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Medical Center Schleswig-Holstein, Arnold-Heller-Straße 3, 24105 Kiel</wicri:regionArea></affiliation></author><author><name sortKey="Levchenko, Evgeny" sort="Levchenko, Evgeny" uniqKey="Levchenko E" first="Evgeny" last="Levchenko">Evgeny Levchenko</name><affiliation wicri:level="1"><nlm:affiliation>Petrov Research Institute of Oncology, 68 Leningradskaya Street, Saint Petersburg 197758, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Petrov Research Institute of Oncology, 68 Leningradskaya Street, Saint Petersburg 197758</wicri:regionArea></affiliation></author><author><name sortKey="Chiarion Sileni, Vanna" sort="Chiarion Sileni, Vanna" uniqKey="Chiarion Sileni V" first="Vanna" last="Chiarion-Sileni">Vanna Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma and Esophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Via Gattamelata 64, 35128 Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma and Esophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Via Gattamelata 64, 35128 Padova</wicri:regionArea></affiliation></author><author><name sortKey="Schachter, Jacob" sort="Schachter, Jacob" uniqKey="Schachter J" first="Jacob" last="Schachter">Jacob Schachter</name><affiliation wicri:level="1"><nlm:affiliation>Oncology Division, Sheba Medical Center, Tel HaShomer, Emek HaEla St 1, Ramat Gan, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Oncology Division, Sheba Medical Center, Tel HaShomer, Emek HaEla St 1, Ramat Gan</wicri:regionArea></affiliation></author><author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University of Tübingen, Geschwister-Scholl-Platz, 72074 Tübingen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Tübingen, Geschwister-Scholl-Platz, 72074 Tübingen</wicri:regionArea></affiliation></author><author><name sortKey="Dutriaux, Caroline" sort="Dutriaux, Caroline" uniqKey="Dutriaux C" first="Caroline" last="Dutriaux">Caroline Dutriaux</name><affiliation wicri:level="1"><nlm:affiliation>Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Saint-André, 1 Rue Jean Burguet, 33000 Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Saint-André, 1 Rue Jean Burguet, 33000 Bordeaux</wicri:regionArea></affiliation></author><author><name sortKey="Gogas, Helen" sort="Gogas, Helen" uniqKey="Gogas H" first="Helen" last="Gogas">Helen Gogas</name><affiliation wicri:level="1"><nlm:affiliation>First Department of Medicine, "Laiko" General Hospital, National and Kapodistrian University of Athens, Athens 157 72, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>First Department of Medicine, "Laiko" General Hospital, National and Kapodistrian University of Athens, Athens 157 72</wicri:regionArea></affiliation></author><author><name sortKey="Mandala, Mario" sort="Mandala, Mario" uniqKey="Mandala M" first="Mario" last="Mandalà">Mario Mandalà</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo</wicri:regionArea></affiliation></author><author><name sortKey="Haanen, John B A G" sort="Haanen, John B A G" uniqKey="Haanen J" first="John B A G" last="Haanen">John B A G. Haanen</name><affiliation wicri:level="1"><nlm:affiliation>Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Céleste" last="Lebbé">Céleste Lebbé</name><affiliation wicri:level="1"><nlm:affiliation>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Mackiewicz, Andrzej" sort="Mackiewicz, Andrzej" uniqKey="Mackiewicz A" first="Andrzej" last="Mackiewicz">Andrzej Mackiewicz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cancer Immunology, Poznan University of Medical Sciences, 15 Garbary Street, 61-866 Poznań, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Cancer Immunology, Poznan University of Medical Sciences, 15 Garbary Street, 61-866 Poznań</wicri:regionArea></affiliation></author><author><name sortKey="Rutkowski, Piotr" sort="Rutkowski, Piotr" uniqKey="Rutkowski P" first="Piotr" last="Rutkowski">Piotr Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Wawelska 15B, 02-034 Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Wawelska 15B, 02-034 Warsaw</wicri:regionArea></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, University Hospital Center, Timone Hospital, Aix Marseille University, 264 Rue St Pierre, 13885 Marseille Cedex 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, University Hospital Center, Timone Hospital, Aix Marseille University, 264 Rue St Pierre, 13885 Marseille Cedex 05</wicri:regionArea></affiliation></author><author><name sortKey="Nathan, Paul" sort="Nathan, Paul" uniqKey="Nathan P" first="Paul" last="Nathan">Paul Nathan</name><affiliation wicri:level="1"><nlm:affiliation>Mount Vernon Cancer Centre, Rickmansworth Road, HA6 2RN Northwood, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Mount Vernon Cancer Centre, Rickmansworth Road, HA6 2RN Northwood</wicri:regionArea></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Hematology/Oncology, UCLA Medical Center, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Hematology/Oncology, UCLA Medical Center, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA</wicri:regionArea></affiliation></author><author><name sortKey="Davies, Michael A" sort="Davies, Michael A" uniqKey="Davies M" first="Michael A" last="Davies">Michael A. Davies</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, TX</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Ying" sort="Zhang, Ying" uniqKey="Zhang Y" first="Ying" last="Zhang">Ying Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ</wicri:regionArea></affiliation></author><author><name sortKey="Kaper, Mathilde" sort="Kaper, Mathilde" uniqKey="Kaper M" first="Mathilde" last="Kaper">Mathilde Kaper</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ</wicri:regionArea></affiliation></author><author><name sortKey="Mookerjee, Bijoyesh" sort="Mookerjee, Bijoyesh" uniqKey="Mookerjee B" first="Bijoyesh" last="Mookerjee">Bijoyesh Mookerjee</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ</wicri:regionArea></affiliation></author><author><name sortKey="Legos, Jeffrey J" sort="Legos, Jeffrey J" uniqKey="Legos J" first="Jeffrey J" last="Legos">Jeffrey J. Legos</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ</wicri:regionArea></affiliation></author><author><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><affiliation wicri:level="1"><nlm:affiliation>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston 02114, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston 02114, MA</wicri:regionArea></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Dermatology Service, Gustave Roussy Comprehensive Cancer Center and Faculty of Medicine, University Paris-South, F-94805, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Dermatology Service, Gustave Roussy Comprehensive Cancer Center and Faculty of Medicine, University Paris-South, F-94805, Villejuif</wicri:regionArea></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Female</term><term>Humans</term><term>Imidazoles (administration & dosage)</term><term>L-Lactate Dehydrogenase (metabolism)</term><term>Male</term><term>Melanoma (drug therapy)</term><term>Melanoma (metabolism)</term><term>Melanoma (pathology)</term><term>Middle Aged</term><term>Neoplasm Metastasis (pathology)</term><term>Oximes (administration & dosage)</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyridones (administration & dosage)</term><term>Pyrimidinones (administration & dosage)</term><term>Risk Factors</term><term>Survival Analysis</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Imidazoles (administration et posologie)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>L-Lactate dehydrogenase (métabolisme)</term><term>Mâle</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (métabolisme)</term><term>Mélanome (traitement médicamenteux)</term><term>Métastase tumorale (anatomopathologie)</term><term>Oximes (administration et posologie)</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Pyridones (administration et posologie)</term><term>Pyrimidinones (administration et posologie)</term><term>Sujet âgé</term><term>Valeur prédictive des tests</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Imidazoles</term><term>Oximes</term><term>Pyridones</term><term>Pyrimidinones</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>L-Lactate Dehydrogenase</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Imidazoles</term><term>Oximes</term><term>Pyridones</term><term>Pyrimidinones</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term><term>Métastase tumorale</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>L-Lactate dehydrogenase</term><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term><term>Neoplasm Metastasis</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Risk Factors</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pronostic</term><term>Sujet âgé</term><term>Valeur prédictive des tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Understanding predictors of long-term benefit with currently available melanoma therapies is the key for optimising individualised treatments. A prior pooled analysis of dabrafenib plus trametinib (D + T)-randomised trials (median follow-up, 20.0 months) identified baseline lactate dehydrogenase (LDH) and number of organ sites with metastasis as predictive factors for progression-free (PFS) and overall (OS) survival. However, longer-term follow-up analyses are needed to confirm which patients treated with D + T can achieve maximum benefit.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28648698</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>26</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.</ArticleTitle><Pagination><MedlinePgn>45-55</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(17)30997-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2017.05.033</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Understanding predictors of long-term benefit with currently available melanoma therapies is the key for optimising individualised treatments. A prior pooled analysis of dabrafenib plus trametinib (D + T)-randomised trials (median follow-up, 20.0 months) identified baseline lactate dehydrogenase (LDH) and number of organ sites with metastasis as predictive factors for progression-free (PFS) and overall (OS) survival. However, longer-term follow-up analyses are needed to confirm which patients treated with D + T can achieve maximum benefit.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three-year landmark data were retrospectively pooled for D + T patients in phase 3 trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]). Univariate and multivariate analyses assessed prognostic values of predefined baseline factors; regression tree analysis determined hierarchy and interactions between variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Long-term pooled outcomes were consistent with individual trial results (N = 563; 3-year PFS, 23%; 3-year OS, 44%). Baseline LDH level and number of organ sites remained strongly associated with and/or predictive of PFS and OS. In addition, baseline sum of lesion diameters (SLD) was identified as a predictor for progression. In the most favourable prognostic group (normal LDH, SLD <66 mm, <3 organ sites; n = 183/563 [33%]), 3-year PFS was 42%. Baseline number of organ sites was also predictive of outcomes in patients with PFS ≥ 6 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Using the largest phase 3 data set available for BRAF/MEK inhibitor combination therapy in melanoma, these results demonstrate that durable responses lasting ≥3 years are possible in subsets of patients with BRAF-mutant melanoma receiving D + T. Although the best predictive model evolved with longer follow-up, factors predicting clinical outcomes with the combination remained consistent with previous analyses.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schadendorf</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; German Cancer Consortium, 69117 Heidelberg, Germany. Electronic address: Dirk.Schadendorf@uk-essen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Georgina V</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Melanoma Institute Australia, The University of Sydney, NSW, Australia; Mater Hospital, North Sydney, NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stroiakovski</LastName><ForeName>Daniil</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Moscow City Oncology Hospital No 62, Moscow 143423, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karaszewska</LastName><ForeName>Boguslawa</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Przychodnia Lekarska KOMED, Wojska Polskiego 6, 62-500 Konin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauschild</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Medical Center Schleswig-Holstein, Arnold-Heller-Straße 3, 24105 Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levchenko</LastName><ForeName>Evgeny</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Petrov Research Institute of Oncology, 68 Leningradskaya Street, Saint Petersburg 197758, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiarion-Sileni</LastName><ForeName>Vanna</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Melanoma and Esophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Via Gattamelata 64, 35128 Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schachter</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Oncology Division, Sheba Medical Center, Tel HaShomer, Emek HaEla St 1, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbe</LastName><ForeName>Claus</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Tübingen, Geschwister-Scholl-Platz, 72074 Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutriaux</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Saint-André, 1 Rue Jean Burguet, 33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gogas</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>First Department of Medicine, "Laiko" General Hospital, National and Kapodistrian University of Athens, Athens 157 72, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandalà</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haanen</LastName><ForeName>John B A G</ForeName><Initials>JBAG</Initials><AffiliationInfo><Affiliation>Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebbé</LastName><ForeName>Céleste</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackiewicz</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cancer Immunology, Poznan University of Medical Sciences, 15 Garbary Street, 61-866 Poznań, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutkowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Wawelska 15B, 02-034 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grob</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Center, Timone Hospital, Aix Marseille University, 264 Rue St Pierre, 13885 Marseille Cedex 05, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathan</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Mount Vernon Cancer Centre, Rickmansworth Road, HA6 2RN Northwood, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribas</LastName><ForeName>Antoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hematology/Oncology, UCLA Medical Center, 100 UCLA Medical Plaza, Suite 550, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaper</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mookerjee</LastName><ForeName>Bijoyesh</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legos</LastName><ForeName>Jeffrey J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover 07936, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston 02114, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Dermatology Service, Gustave Roussy Comprehensive Cancer Center and Faculty of Medicine, University Paris-South, F-94805, Villejuif, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010091">Oximes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011728">Pyridones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>33E86K87QN</RegistryNumber><NameOfSubstance UI="C560077">trametinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.27</RegistryNumber><NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>QGP4HA4G1B</RegistryNumber><NameOfSubstance UI="C561627">dabrafenib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007770" MajorTopicYN="N">L-Lactate Dehydrogenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011744" MajorTopicYN="N">Pyrimidinones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dabrafenib</Keyword><Keyword MajorTopicYN="N">Melanoma</Keyword><Keyword MajorTopicYN="N">Multivariate analysis</Keyword><Keyword MajorTopicYN="N">Trametinib</Keyword><Keyword MajorTopicYN="N">Vemurafenib</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>05</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28648698</ArticleId><ArticleId IdType="pii">S0959-8049(17)30997-8</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2017.05.033</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000640 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000640 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28648698
|texte= Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28648698" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |